Out-patient Clinic, Faculty of Physical Therapy, Horus University
Damietta, Egypt
NCT Number: NCT06870032
Chronic lung diseases (CLDs) such as asthma, cystic fibrosis, and bronchopulmonary dysplasia significantly impact pediatric patients' respiratory function and overall well-being. Pulmonary rehabilitation (PR) has been shown to improve lung function, exercise tolerance, and quality of life in affected individuals. However, limited research has been conducted on PR implementation in Egypt.
Looking for future studies?
Notify Me6 year–16 year
All sexes
Interventional
Not applicable
Damietta, Egypt
Pulmonary rehabilitation significantly enhances respiratory function, exercise capacity, and quality of life in pediatric patients with CLDs while reducing healthcare utilization. These findings highlight the necessity of integrating structured PR programs into pediatric respiratory care in Egypt.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
standard medical care
structured pulmonary rehabilitation program including:
Time frame: at basline and after 12-weeks of intervention
FEV₁ is the volume of air that a person can forcefully exhale in the first second of a forced breath after taking a deep inhalation.
Interpretation of FEV₁:
≥80% of predicted → Normal 60-79% of predicted → Mild obstruction 40-59% of predicted → Moderate obstruction <40% of predicted → Severe obstruction
Time frame: at basline and after 12-weeks of intervention
FVC is the total volume of air that can be forcefully exhaled after taking the deepest possible breath.
Normal Values: Typically ≥80% of the predicted value. Obstructive Lung Disease: FVC may be normal or slightly reduced. Restrictive Lung Disease: FVC is significantly reduced due to decreased lung compliance or lung volume.
Time frame: at basline and after 12-weeks of intervention
PEFR is the maximum speed of expiration achieved after full lung inflation. It is measured in liters per minute (L/min).
ormal values depend on age, sex, and height: Adult males: 450-700 L/min Adult females: 300-500 L/min Reduced PEFR: Suggests airway obstruction, such as in asthma or COPD.
Time frame: at basline and after 12-weeks of intervention
Hospitalization frequency refers to the number of times a patient is admitted to a hospital due to disease exacerbation, complications, or treatment failure.
Number of hospital admissions within a specific time frame (e.g., per year). Length of hospital stay (days per admission). Emergency department visits requiring inpatient care.
Time frame: at basline and after 12-weeks of intervention
Medication dependency refers to the extent to which a patient relies on pharmacological treatment to manage symptoms and maintain functional health.
Frequency and dosage of medication use. Number of rescue medication uses (e.g., bronchodilators in asthma). Reduction or discontinuation of medication over time.
Time frame: at basline and after 12-weeks of intervention
Parental satisfaction refers to how parents perceive the effectiveness, convenience, and overall impact of their child's treatment plan.
Standardized satisfaction surveys (e.g., Likert scale questionnaires). Interviews or focus groups with parents. Feedback on treatment effectiveness, side effects, accessibility, and ease of use.
Horus University
Other
The Impact of Pulmonary Rehabilitation on Respiratory Function and Quality of Life in Pediatric Patients With Chronic Lung Diseases: A Multidisciplinary Approach in Damietta Governorate
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06112730
Chronic Disease, Chronic Lung Disease
New Taipei City, Taiwan
View Trial DetailsNCT03373539
Bronchopulmonary Dysplasia, Chronic Lung Disease
Cleveland, Ohio, United States
View Trial DetailsNCT06174207
Asthma, Bronchial Diseases
Winterthur, Canton of Zurich, Switzerland
View Trial DetailsNCT04037436
Arthritis, Bone Diseases
Cambridge, Ontario, Canada
View Trial Details